Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
224 participants
INTERVENTIONAL
2014-05-31
2014-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
H1 hypothesis: IV dexketoprofen is not equivalent (superior) to placebo in ceasing migraine attack in emergency department.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Intravenous Dexketoprofen and Paracetamol in the Treatment of Headache Caused by Acute Migraine Attack
NCT01730326
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine
NCT04940390
Efficacy and Safety of Intranasal Ketorolac for the Acute Treatment of Migraine
NCT00483717
The Efficacy and Safety of Intra-oral Topical Ketoprofen for the Treatment of Acute Migraine
NCT01228552
Effect of Dexamethasone on Migraine Headache
NCT00733382
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dexketoprofen
50 mg intravenous dexketoprofen in 50 ml normal saline in 5 minutes infusion.
Dexketoprofen
50 mg intravenous arveles in 50 ml saline in 5 minutes
normal slaline
50 ml normal saline
Normal Saline
50 ml normal saline
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dexketoprofen
50 mg intravenous arveles in 50 ml saline in 5 minutes
Normal Saline
50 ml normal saline
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Akdeniz University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Cenker Eken
Associated Proffesor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Faruk Gungor, Pyhsician
Role: PRINCIPAL_INVESTIGATOR
Antalya Training and Govermental Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Antalya Training and Govermental Hospital
Antalya, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Turkcuer I, Serinken M, Eken C, Yilmaz A, Akdag O, Uyan E, Kiray C, Elicabuk H. Intravenous paracetamol versus dexketoprofen in acute migraine attack in the emergency department: a randomised clinical trial. Emerg Med J. 2014 Mar;31(3):182-5. doi: 10.1136/emermed-2013-203044. Epub 2014 Jan 6.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
41/10
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.